Why Ozempic Doesn’t Work for Everyone: The Role of Genetics

Why Some People Lose More Weight on GLP-1 Drugs: The Genetic Connection

The rise of glucagon-like peptide 1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, has fundamentally changed the clinical approach to managing overweight and obesity. However, not everyone experiences the same results. While some patients achieve dramatic weight loss, others see minimal changes or struggle with significant side effects. New research suggests that the answer to this variability lies within our DNA.

The Role of Genetics in Medication Efficacy

A recent genome-wide association study involving 27,885 individuals has provided direct genetic evidence that variation in drug target genes contributes to how people respond to GLP-1 medications. The study identified a specific missense variant in the GLP1R gene that is significantly associated with increased weight loss efficacy. Specifically, each copy of this effect allele is expected to result in an additional −0.76 kg of weight loss.

This discovery is a critical step toward precision medicine in obesity treatment. By understanding the genetic markers that predict success, clinicians may eventually be able to stratify patients by their expected efficacy and risk of side effects before a prescription is even written.

Understanding Side Effects and Genetic Risk

Beyond weight loss, genetics also play a role in how patients tolerate these medications. The research highlighted associations between genetic variations and treatment-related gastrointestinal issues:

• Nausea and Vomiting: Variations in the GLP1R gene are linked to the incidence of these side effects.
• Tirzepatide-Specific Risks: Variation in the GIPR gene is also associated with nausea or vomiting, though this specific genetic link was restricted to patients using tirzepatide.

Broad Health Impacts of GLP-1 Receptor Agonists

While much of the public focus remains on weight loss, GLP-1 receptor agonists impact a wide array of health outcomes. A comprehensive mapping of 175 health outcomes using US Department of Veterans Affairs databases revealed a complex profile of benefits and risks compared to usual care:

Potential Benefits

GLP-1RA employ was associated with a reduced risk of several serious conditions, including:

• Neurocognitive disorders, such as Alzheimer’s disease and dementia.
• Psychotic disorders and substance use.
• Seizures and coagulation disorders.
• Certain infectious illnesses and respiratory conditions.

Potential Risks

Conversely, the study noted an increased risk for specific complications, such as:

• Gastrointestinal disorders.
• Drug-induced pancreatitis.
• Nephrolithiasis (kidney stones) and interstitial nephritis.
• Hypotension, syncope, and arthritic disorders.

Key Takeaways for Patients

Frequently Asked Questions

How do GLP-1 drugs actually work?

GLP-1 receptor agonists mimic a hormone that helps delay gastric emptying and suppress appetite, which aids in overall weight management.

Does this mean there is a genetic test for Ozempic?

While the research identifies genetic predictors in the GLP1R and GIPR genes, these findings currently serve as the foundation for future precision medicine approaches rather than a widely available commercial test.

Why do some people experience more nausea than others?

The variability is partly due to genetic differences in the drug target genes (GLP1R and GIPR), which can make some individuals more susceptible to the medication’s side effects.

The Future of Obesity Treatment

The transition from a “one-size-fits-all” approach to a precision-based model is underway. By leveraging genetic data, healthcare providers will be better equipped to predict which medications will be most effective for an individual and which patients may be at a higher risk for adverse reactions, ensuring safer and more efficient care.